Jiangsu Yunyang Group Pharmaceutical Co., Ltd.

This product is a nucleoside antiviral drug that has a selective inhibitory effect on a variety of herpes viruses (HSV). After acyclovir enters HSV-infected cells, it binds to the specific thymidylate kinase encoded by the virus and is rapidly converted into acyclosine monophosphate, which is then converted into acyclosine diphosphate by the cell guanylate kinase, and then converted into acyclosine triphosphate by other cell enzymes, and competes with guanylate triphosphate to infect herpes simplex virus DNA polymerase, thereby inhibiting viral DNA synthesis. Acyclovir triphosphate is a strong viral DNA polymerase inhibitor, which has an inhibitory effect on the DNA polymerase of five human herpes viruses, namely HSV-1, HSV-2, VZV, CMZ and EBV, and has no effect on normal cells. Its antiviral efficacy is 160 times stronger than that of adenosine.

It has the effect of directly stimulating vascular α1 receptors and causing vasoconstriction, thereby alleviating congestion and edema caused by inflammation.

Timolol maleate is a non-selective β-adrenergic receptor blocker with no obvious endogenous sympathomimetic activity and local anesthetic effect, and no direct inhibitory effect on the myocardium. This product is timolol maleate eye drops, which can reduce intraocular pressure in patients with high intraocular pressure and normal people. The exact mechanism of reducing intraocular pressure is still unclear. Tonometry and aqueous humor fluorescence studies suggest that the intraocular pressure-lowering effect of this product is related to reducing aqueous humor production.